Carlos Cruchaga
Barbara Burton & Reuben Morriss III Professor
- Phone: 314-286-0546
- Email: cruchagac@nospam.wustl.edu
Additional Titles & Roles
- Professor of Neurology
- Professor of Genetics
- Professor of Genetics
- Professor of Neurology
- Knight-ADRC Genetics and Hight-throughput Omics Core leader
- DIAN (The Dominantly Inherited Alzheimer Network) Genetics Core co-leader
- Scientific advisor McDonnell Genome Institute (MGI)
- Director NeuroGenomics and Informatics lab
Education & Training
- Ph.D.: University of Navarra, 2005
- M.S.: University of Navarra, 2002
- B.S.: University of Navarra, 2000
Research Interests
Dr. Cruchaga is a human genomicist with expertise in multiomics, informatics, and neurodegeneration. He completed his PhD in Biochemistry and Molecular Biology in 2005 at the University of Navarra in Spain. During his first postdoc with Dr. Pastor he conducted statistical human genetics studies focused on Alzheimer’s disease (AD) and Parkinson’s disease (PD). He then moved to Dr. Goate’s Lab to complete his training in quantitative human genomics. Dr. Cruchaga established his laboratory at Washington University in 2011 to study the genetic architecture of neurodegenerative diseases. His interests are focused on using human genomic and other -omic data (proteomics, metabolomics, and lipidomics) to identify and understand the biological processes that lead to AD, PD, frontotemporal dementia, and other neurodegenerative processes. He is the founding director of the NeuroGenomics and Informatics Center at Washington University.
Recent Publications
-
The LRRK2 p.L1795F variant causes Parkinson’s disease in the European population
the Global Parkinson’s Genetics Program (GP2), Dec 2025, In: npj Parkinson’s Disease. 11, 1, 58.
-
Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer’s disease
Dominantly Inherited Alzheimer Network (DIAN), Dec 2025, In: Alzheimer’s Research and Therapy. 17, 1, 5.
-
Cross-ancestry genome-wide association study identifies implications of SORL1 in cerebral beta-amyloid deposition
Kim, J. P., Jung, S. H., Jang, B., Cho, M., Song, M., Kim, J., Kim, B., Lee, H., Shin, D., Lee, E. H., Jang, H., Kim, B. H., Ham, H., Kim, D., Raj, T., Cruchaga, C., Kim, H. J., Na, D. L., Seo, S. W. & Won, H. H., Dec 2025, In: Nature communications. 16, 1, 3150.
-
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial
Dominantly Inherited Alzheimer’s Disease–Trials Unit, Apr 2025, In: The Lancet Neurology. 24, 4, p. 316-330 15 p.
-
Local genetic covariance analysis with lipid traits identifies novel loci for early-onset Alzheimer’s Disease
Alzheimer’s Disease Genetics Consortium, Mar 17 2025, In: PLoS genetics. 21, 3 March, e1011631.